NAD+ went from biochemistry textbooks to supplement shelves and infusion menus in under a decade. The biology is real; the claims often run ahead of it. A plain-language look at what the evidence currently supports, what remains unproven, and the questions to ask before booking anything.
NAD+ has had an unusually loud decade. Nicotinamide adenine dinucleotide, a coenzyme present in every cell in the body, went from a molecule known mainly to biochemists to a fixture of longevity conversation, supplement shelves and infusion menus.
The biology is genuinely interesting. The claims layered on top of it often run ahead of the evidence.
What NAD+ does
NAD+ is central to energy metabolism. It acts as an electron carrier in the reactions that convert food into ATP, the currency cells spend to do anything at all. Without enough NAD+, that conversion becomes less efficient.
It is also a substrate, meaning it gets consumed, for two families of enzymes that have drawn considerable research attention. Sirtuins are involved in cellular stress responses and metabolic regulation. PARPs are involved in DNA repair. Both need NAD+ to work, and both draw down the available pool when active.
That double role is why researchers studying ageing pay attention to it. NAD+ is fuel that repair processes compete for.
The decline, and its caveats
Multiple studies have reported that NAD+ levels fall with age across a range of tissues. The finding is reasonably consistent, though the magnitude varies a lot depending on the tissue examined and the method used to measure it, which is a real limitation when comparing studies.
The intuitive next step is that restoring NAD+ should reverse age-related decline. This is where the reasoning outpaces the data. A correlation between falling levels and ageing does not establish that the fall causes the decline, nor that raising levels reverses it. Both remain open questions.
What supplementation trials show
Most human research has used oral precursors rather than NAD+ itself: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).
The most consistent finding is that oral precursors can raise blood NAD+ levels. That is best established for nicotinamide riboside; the evidence base for NMN is thinner and more mixed.
Less consistent is what the increase actually produces. Trials have reported modest effects on some metabolic and inflammatory measures, but results have varied, sample sizes have generally been small, and durations short. Several well-conducted studies found no significant effect on the functional outcomes they measured. Safety at the doses studied has generally been acceptable, with gastrointestinal effects the most commonly reported issue.
So: raising NAD+ is achievable. Showing that it produces meaningful clinical benefit in healthy adults is still in progress.
The intravenous route
Intravenous NAD+ bypasses the digestive tract and delivers the molecule directly into circulation. The rationale offered is bioavailability: oral precursors have to be absorbed and converted, an infusion does not.
There is a reasonable pharmacological argument here. There is also considerably less controlled trial data on intravenous NAD+ than on oral precursors, and what exists is largely small, short-term, or focused on specific clinical populations rather than healthy adults seeking general benefit. Intravenous NAD+ is not approved by any regulator as a treatment for a specific medical condition; it is used as a supportive measure and should be discussed with a qualified clinician beforehand.
Practically, infusions are slow. Rapid administration is associated with chest tightness, nausea, cramping and flushing, which is why sessions are typically extended over one to several hours and the rate adjusted to tolerance. This is a medical procedure and needs clinical supervision, including a review of medical history and current medications beforehand. Providers offering nad iv therapy bangkok and similar programmes should be assessing suitability before administering anything, not simply taking a booking.
Where the evidence actually stands
The biology is real and the research is active. This is not a fringe area. But the strongest human data concerns raising NAD+ levels, not the downstream clinical benefits of doing so, and anyone presenting the second as settled is overstating the case. Individual response appears to vary, for reasons that are not well understood.
It is a supportive measure rather than a treatment for a diagnosed condition. If fatigue is the presenting problem, it is worth establishing why before reaching for an infusion. Thyroid dysfunction, iron deficiency, sleep apnoea and depression all produce similar symptoms and all have specific, established treatments. An infusion given in place of that workup is a missed diagnosis.
NAD+ sits in an awkward but familiar position. A well-characterised molecule, a plausible mechanism, active research, and a commercial market that has moved faster than the evidence behind it.
That does not make it worthless. It makes it early. Interest without certainty is the reasonable stance, alongside a clinician willing to tell you which parts are established and which are not.Seemore: